Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $45.00 price target on the stock, up previously from $34.00.
LowReport
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) was upgraded by analysts at SVB Leerink LLC from a "market perform" rating to an "outperform" rating. They now have a $45.00 price target on the stock, up previously from $34.00.
TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
LowReport
TANDEM ALERT: Bragar Eagel & Squire, P.C. is Investigating Tandem Diabetes Care, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target raised by analysts at Stifel Nicolaus from $37.00 to $40.00. They now have a "buy" rating on the stock.
LowReport
Tandem Diabetes Care, Inc. (NASDAQ: TNDM) had its price target raised by analysts at Stifel Nicolaus from $37.00 to $40.00. They now have a "buy" rating on the stock.
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
"Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below:
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ blog email newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our blog below: